Literature DB >> 21823042

Deregulated transcription factors in leukemia.

Yutaka Shima1, Issay Kitabayashi2.   

Abstract

Specific chromosomal translocations and other mutations associated with acute myeloblastic leukemia (AML) often involve transcription factors and transcriptional coactivators. Such target genes include AML1, C/EBPα, RARα, MOZ, p300/CBP, and MLL, all of which are important in the regulation of hematopoiesis. The resultant fusion or mutant proteins deregulate the transcription of the affected genes and disrupt their essential role in hematopoiesis, causing differentiation block and abnormal proliferation and/or survival. This review focuses on such transcription factors and coactivators, and describes their roles in leukemogenesis and hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823042     DOI: 10.1007/s12185-011-0905-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  100 in total

1.  Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias.

Authors:  Daniela Cilloni; Sonia Carturan; Enrico Gottardi; Francesca Messa; Emanuela Messa; Milena Fava; Daniela Diverio; Angelo Guerrasio; Francesco Lo-Coco; Giuseppe Saglio
Journal:  Blood       Date:  2003-10-01       Impact factor: 22.113

2.  C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.

Authors:  Vijaya Vegesna; Seisho Takeuchi; Wolf-K Hofmann; Takayuki Ikezoe; Sigal Tavor; Utz Krug; Anthony C Fermin; Anthony Heaney; Carl W Miller; H Phillip Koeffler
Journal:  Leuk Res       Date:  2002-05       Impact factor: 3.156

3.  C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.

Authors:  Yue-Ying Wang; Li-Juan Zhao; Chuan-Feng Wu; Ping Liu; Lin Shi; Yang Liang; Shu-Min Xiong; Jian-Qing Mi; Zhu Chen; Ruibao Ren; Sai-Juan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

4.  Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.

Authors:  J Liang; L Prouty; B J Williams; M A Dayton; K L Blanchard
Journal:  Blood       Date:  1998-09-15       Impact factor: 22.113

5.  ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.

Authors:  J Wang; T Hoshino; R L Redner; S Kajigaya; J M Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

6.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

Authors:  R L Redner; E A Rush; S Faas; W A Rudert; S J Corey
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

7.  A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity.

Authors:  F T Lin; O A MacDougald; A M Diehl; M D Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

8.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Authors:  Rajani K Vangala; Marion S Heiss-Neumann; Janki S Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

10.  The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion.

Authors:  S P Romana; M Mauchauffé; M Le Coniat; I Chumakov; D Le Paslier; R Berger; O A Bernard
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

View more
  17 in total

Review 1.  Histone-modifying enzymes: regulators of developmental decisions and drivers of human disease.

Authors:  Jill S Butler; Evangelia Koutelou; Andria C Schibler; Sharon Y R Dent
Journal:  Epigenomics       Date:  2012-04       Impact factor: 4.778

2.  Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.

Authors:  Haruko Shima; Kazutsune Yamagata; Yukiko Aikawa; Mika Shino; Haruhiko Koseki; Hiroyuki Shimada; Issay Kitabayashi
Journal:  Int J Hematol       Date:  2013-11-21       Impact factor: 2.490

Review 3.  Histone modifications: Targeting head and neck cancer stem cells.

Authors:  John M Le; Cristiane H Squarize; Rogerio M Castilho
Journal:  World J Stem Cells       Date:  2014-11-26       Impact factor: 5.326

Review 4.  Targeting deregulated epigenetic control in cancer.

Authors:  Sayyed K Zaidi; Andre J Van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-11       Impact factor: 6.384

5.  Transposon mutagenesis reveals cooperation of ETS family transcription factors with signaling pathways in erythro-megakaryocytic leukemia.

Authors:  Jian Zhong Tang; Catherine L Carmichael; Wei Shi; Donald Metcalf; Ashley P Ng; Craig D Hyland; Nancy A Jenkins; Neal G Copeland; Viive M Howell; Zhizhuang Joe Zhao; Gordon K Smyth; Benjamin T Kile; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

Review 6.  Gene mutations of acute myeloid leukemia in the genome era.

Authors:  Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2013-01-29       Impact factor: 2.490

Review 7.  Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy.

Authors:  Leila Haery; Ryan C Thompson; Thomas D Gilmore
Journal:  Genes Cancer       Date:  2015-05

8.  Novel insights into the genetic controls of primitive and definitive hematopoiesis from zebrafish models.

Authors:  Raman Sood; Paul Liu
Journal:  Adv Hematol       Date:  2012-07-25

9.  Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation.

Authors:  Pei-Yi Chen; Jui-Hung Yen; Ruey-Ho Kao; Ji-Hshiung Chen
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

Review 10.  Genome-scale technology driven advances to research into normal and malignant haematopoiesis.

Authors:  Berthold Göttgens
Journal:  Scientifica (Cairo)       Date:  2012-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.